6461 logo

Intech Biopharm Corporation Stock Price

TPEX:6461 Community·NT$3.1b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

6461 Share Price Performance

NT$17.40
-2.15 (-11.00%)
NT$17.40
-2.15 (-11.00%)
Price NT$17.40

6461 Community Narratives

There are no narratives available yet.

Trending Discussion

No trending discussion available.

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Slight risk with weak fundamentals.

4 Risks
0 Rewards

Intech Biopharm Corporation Key Details

NT$117.5m

Revenue

NT$230.2m

Cost of Revenue

-NT$112.7m

Gross Profit

NT$299.8m

Other Expenses

-NT$412.5m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-2.31
-95.94%
-351.13%
127.8%
View Full Analysis

About 6461

Founded
2010
Employees
96
CEO
Manish Chawla
WebsiteView website
www.intechbiopharm.com

Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. The company offers combinations, formulations, and generic drugs for the treatment of respiratory diseases using technology platforms, such as inhaled low ethanol formulation, a metered dose inhaler platform for treating asthma and COPD, as well as dry powder inhaler that comprises blisters and capsules. Its products include SYN006, SYN010, SYN007, Synflutide, Duasma,Synvent, and SYN011. The company was founded in 2010 and is headquartered in Taipei, Taiwan.

Recent 6461 News & Updates

Recent updates

No updates